ria

Rakesh Kumar Singhal

@ca.rakesh.singhal.7960
New Delhi
5+ Years of experience
SEBI Registration INH100003282
I'm Rakesh Kumar Singhal, a qualified Chartered Accountant and Certified Technical Analyst with more than a decade of experience in the equity markets, based in New Delhi. Investrocker is my group for sharing rock-solid investment ideas, grounded in value investing and the CANSLIM strategy for momentum. I identify fund ... Read more
Trade Ideas
228
Opinions
479
Followers
119k

Expertise

Quantitative
Growth
Technical
Index Strategies
Swing Trading
Market Commentary
Futures & Options
Technical Analysis
Trade Facts
Total Trades
0
Missed Trades
0
Profit Trades
0
icon0%
Accuracy
Ask me Anything

Got a question? Ask me and I will answer it. Stay curious, stay hungry!

Posts

shared an insight ⚡️ 5 hours ago
INFO EDGE Quarterly Results Analysis-Q2FY2027
NAUKRI Financial performance and key operating metrics (Consolidated) : Operating Revenue for Q2FY27 is Rs. 904 Crs., 12.22% growth YoY, Total Income is Rs. 1,332 Crs., 37.75% growth YoY, EBITDA is Rs. 782 Crs., 77.56% growth YoY, EBITDA Margin is 58.73% improved by 1317 Basis points YoY, PBT Rs. 748 Crs., 74.39% growth YoY, PAT Rs. 650 Crs., 86.98% growth YoY. But On QoQ basis Op. Revenue is flat up by 2.63%, Total Income is up by 24.17%, EBITDA is up by 46.77%, PBT is up by 18.37% PAT is also up by 32.59%. Recruitment (Naukri) : underlying growth 14–15%, AI monetization scaling, margin resilience : Q2 Recruitment: Billings +13%, revenue +13%; Operating profit +20%, OPBT margin 59%; 99acres (Real Estate) : accelerating growth, sharp loss reduction, emerging operating leverage : Q2 billings +21% (vs +17% in Q1), revenue +17%, Profitability inflection: operating losses cut 93% to <₹2cr (from ₹23cr LY). Matchmaking (Jeevansathi + Aisle) : growth with near breakeven economics :Segment billings +23%: Jeevansathi +18%, Aisle +40%, Segment near breakeven at OPBT: Jeevansathi ₹2cr profit, Aisle ₹3cr loss. Education (Shiksha) :structural disruption from AI search; pivot underway with controlled losses : Billings -27%, revenue -9%, near breakeven OPBT, but operating cash loss -₹16cr. Portfolio spans 135 companies across AI/deeptech/consumer tech; ₹5,000cr invested via balance sheet and AIFs; some listed and others raised follow-on rounds
75
74
shared an insight ⚡️ 9 hours ago
KPR MILSS Quarterly Results Analysis-Q2FY2027
KPRMILL : Financial performance and key operating metrics (Consolidated) : Operating Revenue for Q2FY27 is Rs. 1,940 Crs., 18.85% growth YoY, Total Income is Rs. 1,989 Crs., 20.1% growth YoY, Gross Profit is Rs. 862 Crs., 33.6% growth YoY, EBITDA is Rs. 547 Crs., 61.7% growth YoY, EBITDA Margin is 27.49% improved by 707 Basis points YoY, PBT Rs. 479 Crs., 76.2% growth YoY, PAT Rs. 345 Crs., 58.24% growth YoY. But On QoQ basis Op. Revenue is flat up by 0.2%, Total Income is flat up by 0.9%, EBITDA is up by 33.5%, PBT is up by 41.6% PAT is also up by 33.44%. Strong EBITDA and PAT margins show operational efficiency. Equity base has grown; net borrowings/debt have dropped significantly, indicating financial robustness. Return on capital employed and cash reserves have increased. Europe is the biggest export market, followed by North America, Australia, and Asia. H1FY27 : Yarn & Fabric Sales Volume 36,574 MT, Garment Sales Volume 90.3 Mn., Sugar Sales Volume 99,528 MT, Ethanol Sales Volume 643.73 Lac Ltrs.
130
44
shared an insight ⚡️ 3rd Nov
PIRAMAL PHARMA Results Analysis-Q2FY2027
PPLPHARMA Financial performance and key operating metrics (Consolidated) : Operating Revenue for Q2FY27 is Rs. 2,617 Crs., 28.05% growth YoY, Total Income is Rs. 2,653 Crs., 25.77% growth YoY, Gross Profit is Rs. 1,711 Crs., 27.56% growth YoY, EBITDA is Rs. 385 Crs., 71.51% growth YoY, EBITDA Margin is 14.5% improved by 387 Basis points YoY, PBT Rs. 82 Crs. in comparison to loss of Rs. 46 Cr. in PY, PAT Rs. 5 Crs. in comparison to loss of Rs. 99 Cr. in PY. On QoQ basis Op. Revenue is up by 15.29%, Total Income is up by 12.45%, EBITDA is up by 35.16%, PBT turned profitable from loss of Rs. 7 Cr., PAT is also turned profitable from loss of Rs. 69 Cr. Margin step-up primarily to operating leverage from better capacity utilization, with disciplined execution, productivity and cost management. CDMO : Q2 CDMO revenue: ₹1,424 cr (+36% YoY), Complex Hospital Generics (CHG) : Q2 CHG revenue: ₹849 cr (+32% YoY) Consumer Healthcare: Q2 revenue: ₹359 cr (+13% YoY) Net debt increased over six months due to Lexington expansion, Kenalog acquisition, and currency impact.
1053
76
    Read More Posts →

    FAQ's

    What are the top stock recommendations by Rakesh Kumar Singhal?

    up
    Rakesh Kumar Singhal regularly shares stock views and market analysis on StockGro. Some of the stocks they have recently shared views on include NAUKRI, KPRMILL and PPLPHARMA. Explore Rakesh Kumar Singhal's complete list of posts and trade views on their StockGro profile.

    How can I follow Rakesh Kumar Singhal's latest investment insights?

    up
    You can follow Rakesh Kumar Singhal's latest investment insights, stock recommendations, and market analysis on StockGro App. Additionally, you can check their detailed stock analysis reports in the StockGro blog section.

    What is Rakesh Kumar Singhal's investment strategy?

    up
    Rakesh Kumar Singhal follows a data-driven, research-backed investment strategy focused on maximizing returns while managing risk. Their approach includes fundamental and technical analysis, portfolio diversification, and sectoral trends to identify high-potential stocks.

    How long has Rakesh Kumar Singhal been a SEBI-registered Research Analyst (RA)?

    up
    Rakesh Kumar Singhal has been a SEBI-registered Research Analyst and have 5+ Years of experience. With extensive experience in stock market analysis and investment research, they have guided investors in making informed and profitable decisions.

    Where can I see Rakesh Kumar Singhal's past performance and stock picks?

    up
    You can check Rakesh Kumar Singhal's past stock recommendations, success rate, and investment insights on their StockGro profile. Their historical stock picks reflect a track record of strategic investment decisions based on thorough research.

    How can I contact Rakesh Kumar Singhal for stock market advice?

    up
    For stock market guidance from Rakesh Kumar Singhal, you can connect through their StockGro profile. Some RAs may also provide personalized investment consultations based on their availability and SEBI regulations.

    What is Rakesh Kumar Singhal's track record in predicting market movements?

    up
    Rakesh Kumar Singhal has a proven track record of accurate market analysis and trend predictions. By analyzing economic indicators, market sentiment, and technical charts, they have consistently helped investors make well-timed investment decisions.

    What is the SEBI Registration number for Rakesh Kumar Singhal?

    up
    Rakesh Kumar Singhal is a SEBI-registered Research Analyst with the SEBI Registration INH100003282. This ensures that their investment recommendations comply with SEBI's regulatory framework for investor protection and financial advisory standards.
    Be Financially Free with StockGro